NBT Bank’s Haemonetics HAE Stock Holding History

NBT Bank’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.05K	Hold	14	–	–	﹤0.01%	976
2026 Q1	$789	Buy	+14	New	+$912	﹤0.01%	982

Other funds holding HAE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

NBT Bank's HAE Position: Q2 2026 in Review

NBT Bank held its Haemonetics (HAE) position steady in Q2 2026 at 14 shares worth $1.05K. The position accounts for ﹤0.01% of the portfolio, ranked #976.

NBT Bank first reported a position in HAE in Q1 2026 and has held it in 2 quarters since. 329 funds tracked by Wall St. Rank hold HAE as of Q2 2026.

NBT Bank held 14 shares of Haemonetics worth $1.05K as of Q2 2026.
NBT Bank left its Haemonetics share count unchanged in Q2 2026.
Haemonetics made up ﹤0.01% of NBT Bank's portfolio in Q2 2026, its #976 holding.
NBT Bank first reported a position in Haemonetics in Q1 2026 and has held it in 2 quarters since.
329 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.

Based on NBT Bank's 13F filing for Q2 2026, filed 29 Jul 2026.